DOP2016000284A - Proteínas agonistas de los receptores de trail de cadena simple. - Google Patents
Proteínas agonistas de los receptores de trail de cadena simple.Info
- Publication number
- DOP2016000284A DOP2016000284A DO2016000284A DO2016000284A DOP2016000284A DO P2016000284 A DOP2016000284 A DO P2016000284A DO 2016000284 A DO2016000284 A DO 2016000284A DO 2016000284 A DO2016000284 A DO 2016000284A DO P2016000284 A DOP2016000284 A DO P2016000284A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- trail
- agonist proteins
- receivers
- single chain
- proteins
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 239000000556 agonist Substances 0.000 title abstract 3
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 abstract 2
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 abstract 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 1
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 abstract 1
- 108700012411 TNFSF10 Proteins 0.000 abstract 1
- 229940123369 TRAIL receptor agonist Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Abstract
Proteínas específicas que son agonistas de los receptores de TRAIL. Ácidos nucleicos que las codifican. Métodos para tratar una enfermedad o un trastorno asociado a los TRAIL en un sujeto. Las proteínas agonistas de los receptores de TRAIL que se proveen en la presente comprenden tres dominios de TRAIL solubles y un fragmento Fc. Las proteínas agonistas de los receptores de TRAIL no forman agregados de manera sustancial y son apropiadas para aplicaciones terapéuticas, de diagnóstico y/o de investigación. fig. 17B
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983152P | 2014-04-23 | 2014-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2016000284A true DOP2016000284A (es) | 2017-02-15 |
Family
ID=53055121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2016000284A DOP2016000284A (es) | 2014-04-23 | 2016-10-19 | Proteínas agonistas de los receptores de trail de cadena simple. |
Country Status (38)
| Country | Link |
|---|---|
| US (5) | US9908927B2 (es) |
| EP (2) | EP3366699A1 (es) |
| JP (2) | JP6523331B2 (es) |
| KR (2) | KR102079919B1 (es) |
| CN (2) | CN106459221B (es) |
| AR (1) | AR100168A1 (es) |
| AU (3) | AU2015249649B2 (es) |
| BR (1) | BR112016024515B1 (es) |
| CA (2) | CA2946402C (es) |
| CL (1) | CL2016002683A1 (es) |
| CR (1) | CR20160516A (es) |
| CY (1) | CY1120281T1 (es) |
| DK (1) | DK3134430T3 (es) |
| DO (1) | DOP2016000284A (es) |
| EC (1) | ECSP16089579A (es) |
| ES (1) | ES2672368T3 (es) |
| HR (1) | HRP20180950T1 (es) |
| HU (1) | HUE038914T2 (es) |
| IL (2) | IL248244B (es) |
| LT (1) | LT3134430T (es) |
| MA (2) | MA39770A (es) |
| MX (2) | MX2016013858A (es) |
| MY (1) | MY181986A (es) |
| NO (1) | NO2776305T3 (es) |
| PE (1) | PE20170299A1 (es) |
| PH (2) | PH12020500377A1 (es) |
| PL (1) | PL3134430T3 (es) |
| PT (1) | PT3134430T (es) |
| RS (1) | RS57153B1 (es) |
| RU (1) | RU2699285C2 (es) |
| SG (3) | SG10201806465TA (es) |
| SI (1) | SI3134430T1 (es) |
| SM (1) | SMT201800286T1 (es) |
| TR (1) | TR201806912T4 (es) |
| TW (2) | TWI747178B (es) |
| UA (1) | UA118286C2 (es) |
| UY (1) | UY36095A (es) |
| WO (1) | WO2015164588A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2754432T3 (es) * | 2015-05-04 | 2020-04-17 | Apogenix Ag | Proteínas agonistas de receptor CD40 de cadena sencilla |
| EP3364995B1 (en) | 2015-10-23 | 2021-08-04 | Apogenix AG | Single-chain cd27-receptor agonist proteins |
| AU2016341402B2 (en) * | 2015-10-23 | 2020-08-27 | Apogenix Ag | Single-chain GITR-receptor agonist proteins |
| CN108699129A (zh) | 2015-10-23 | 2018-10-23 | 阿珀吉科吉尼科斯股份公司 | 单链light受体激动剂蛋白 |
| WO2017102010A1 (en) * | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
| JP7091248B2 (ja) | 2016-03-01 | 2022-06-27 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ | 低減されたｌ－グルタミナーゼ活性および増強された安定性を有するｌ－アスパラギナーゼ変異体および融合タンパク質 |
| CN108884142A (zh) * | 2016-03-16 | 2018-11-23 | 梅里麦克制药股份有限公司 | 用于癌症治疗的工程化trail |
| US10501744B2 (en) | 2016-05-04 | 2019-12-10 | Indiana University Research And Technology Corporation | Presentation of bioactive proteins |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| AU2017283487A1 (en) * | 2016-06-13 | 2018-11-22 | Merrimack Pharmaceuticals, Inc. | Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| CA3106549A1 (en) * | 2017-08-11 | 2019-02-14 | The Board Of Trustees Of The University Of Illinois | Truncated guinea pig l-asparaginase variants and methods of use |
| WO2019178433A1 (en) | 2018-03-15 | 2019-09-19 | Abbvie Inc. | Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer |
| WO2019178438A1 (en) | 2018-03-15 | 2019-09-19 | Abbvie Inc. | Abbv-621 in combination with anti-cancer agents for the treatment of cancer |
| CN115836084A (zh) | 2020-05-15 | 2023-03-21 | 阿珀吉尼科斯股份公司 | 多特异性免疫调节剂 |
| EP4346885A1 (en) | 2021-05-28 | 2024-04-10 | Julius-Maximilians-Universität Würzburg | Recombinant proteinaceous binding molecules |
| WO2023088876A1 (en) | 2021-11-16 | 2023-05-25 | Apogenix Ag | Multi-specific immune modulators |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7645700A (en) | 1999-10-07 | 2001-05-10 | Maxygen Aps | Single-chain antagonist polypeptides |
| DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| CA2314199A1 (en) | 2000-07-21 | 2002-01-21 | Robert Simoneau | C-chip |
| ATE437891T1 (de) | 2000-12-07 | 2009-08-15 | Lilly Co Eli | Glp-1 fusionsproteine |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7538088B2 (en) * | 2002-04-26 | 2009-05-26 | California Institute Of Technology | Method for inhibiting angiogenesis by administration of the extracellular domain of D1-1 polypeptide |
| DE102004014983A1 (de) | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
| US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
| CA2597789A1 (en) * | 2005-04-15 | 2006-10-19 | Rappaport Family Institute For Research In The Medical Sciences | Molecules and methods of using same for treating mcp-1/ccr2 associated diseases |
| JP5255435B2 (ja) | 2005-04-26 | 2013-08-07 | メディミューン，エルエルシー | ヒンジドメイン操作による抗体エフェクター機能の調節 |
| EP1894940A1 (en) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | TNF superfamily fusion proteins |
| EP3321277B1 (en) | 2007-07-10 | 2019-09-18 | Apogenix AG | Tnf superfamily collectin fusion proteins |
| EP3002299A1 (en) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
| HUE025236T2 (en) | 2008-07-21 | 2016-03-29 | Apogenix Gmbh | TNFSF single chain molecules |
| US20110287001A1 (en) * | 2008-09-22 | 2011-11-24 | Tetralogic Pharmaceuticals | Method of treatment |
| CA2739663A1 (en) * | 2008-10-10 | 2010-05-15 | Anaphore, Inc. | Polypeptides that bind trail-r1 and trail-r2 |
| EP2382236B1 (en) | 2009-01-09 | 2016-08-17 | Apogenix AG | Fusion proteins forming trimers |
| EP2389192A4 (en) * | 2009-01-23 | 2013-01-16 | Biogen Idec Inc | STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE |
| CA2785139A1 (en) | 2009-12-22 | 2011-06-30 | Novartis Ag | Tetravalent cd47-antibody constant region fusion protein for use in therapy |
| JP6041799B2 (ja) | 2010-04-13 | 2016-12-14 | メディミューン，エルエルシー | Ｔｒａｉｌｒ２特異的多量体足場 |
| US9764038B2 (en) * | 2011-12-23 | 2017-09-19 | Innate Pharma | Enzymatic conjugation of antibodies |
| SG11201500134QA (en) * | 2012-07-18 | 2015-03-30 | Apogenix Gmbh | Composition comprising a mixture of cd95-fc isoforms |
-
2012
- 2012-11-06 NO NO12790406A patent/NO2776305T3/no unknown
-
2015
- 2015-04-23 RU RU2016145608A patent/RU2699285C2/ru active
- 2015-04-23 ES ES15721089.9T patent/ES2672368T3/es active Active
- 2015-04-23 CR CR20160516A patent/CR20160516A/es unknown
- 2015-04-23 SM SM20180286T patent/SMT201800286T1/it unknown
- 2015-04-23 MX MX2016013858A patent/MX2016013858A/es active IP Right Grant
- 2015-04-23 TR TR2018/06912T patent/TR201806912T4/tr unknown
- 2015-04-23 JP JP2016564068A patent/JP6523331B2/ja not_active Expired - Fee Related
- 2015-04-23 BR BR112016024515-6A patent/BR112016024515B1/pt not_active IP Right Cessation
- 2015-04-23 SG SG10201806465TA patent/SG10201806465TA/en unknown
- 2015-04-23 WO PCT/US2015/027270 patent/WO2015164588A1/en not_active Ceased
- 2015-04-23 AU AU2015249649A patent/AU2015249649B2/en not_active Ceased
- 2015-04-23 UA UAA201611802A patent/UA118286C2/uk unknown
- 2015-04-23 PH PH1/2020/500377A patent/PH12020500377A1/en unknown
- 2015-04-23 CN CN201580031858.7A patent/CN106459221B/zh not_active Expired - Fee Related
- 2015-04-23 SG SG10202111785VA patent/SG10202111785VA/en unknown
- 2015-04-23 US US14/694,358 patent/US9908927B2/en active Active
- 2015-04-23 EP EP18155146.6A patent/EP3366699A1/en not_active Withdrawn
- 2015-04-23 SI SI201530223T patent/SI3134430T1/en unknown
- 2015-04-23 TW TW109106778A patent/TWI747178B/zh not_active IP Right Cessation
- 2015-04-23 DK DK15721089.9T patent/DK3134430T3/en active
- 2015-04-23 PT PT157210899T patent/PT3134430T/pt unknown
- 2015-04-23 AR ARP150101224A patent/AR100168A1/es active IP Right Grant
- 2015-04-23 CA CA2946402A patent/CA2946402C/en active Active
- 2015-04-23 PL PL15721089T patent/PL3134430T3/pl unknown
- 2015-04-23 UY UY0001036095A patent/UY36095A/es active IP Right Grant
- 2015-04-23 RS RS20180450A patent/RS57153B1/sr unknown
- 2015-04-23 MA MA039770A patent/MA39770A/fr unknown
- 2015-04-23 CA CA3184067A patent/CA3184067A1/en active Pending
- 2015-04-23 KR KR1020167032819A patent/KR102079919B1/ko not_active Expired - Fee Related
- 2015-04-23 SG SG11201608767XA patent/SG11201608767XA/en unknown
- 2015-04-23 TW TW104113087A patent/TWI683825B/zh not_active IP Right Cessation
- 2015-04-23 LT LTEP15721089.9T patent/LT3134430T/lt unknown
- 2015-04-23 MA MA045069A patent/MA45069A/fr unknown
- 2015-04-23 KR KR1020197035100A patent/KR20190135546A/ko not_active Ceased
- 2015-04-23 CN CN202010767219.XA patent/CN111718424A/zh active Pending
- 2015-04-23 HR HRP20180950TT patent/HRP20180950T1/hr unknown
- 2015-04-23 HU HUE15721089A patent/HUE038914T2/hu unknown
- 2015-04-23 PE PE2016002016A patent/PE20170299A1/es unknown
- 2015-04-23 MY MYPI2016703814A patent/MY181986A/en unknown
- 2015-04-23 EP EP15721089.9A patent/EP3134430B1/en active Active
-
2016
- 2016-10-07 IL IL248244A patent/IL248244B/en active IP Right Grant
- 2016-10-19 DO DO2016000284A patent/DOP2016000284A/es unknown
- 2016-10-19 PH PH12016502079A patent/PH12016502079A1/en unknown
- 2016-10-21 MX MX2019013587A patent/MX2019013587A/es unknown
- 2016-10-21 CL CL2016002683A patent/CL2016002683A1/es unknown
- 2016-11-23 EC ECIEPI201689579A patent/ECSP16089579A/es unknown
-
2018
- 2018-02-02 US US15/887,509 patent/US20180222962A1/en not_active Abandoned
- 2018-05-25 CY CY20181100568T patent/CY1120281T1/el unknown
- 2018-11-30 AU AU2018271369A patent/AU2018271369B2/en not_active Ceased
-
2019
- 2019-04-24 JP JP2019082671A patent/JP6714751B2/ja not_active Expired - Fee Related
-
2020
- 2020-02-11 IL IL272612A patent/IL272612A/en unknown
- 2020-03-30 AU AU2020202247A patent/AU2020202247A1/en not_active Abandoned
- 2020-08-14 US US16/993,569 patent/US20210040178A1/en not_active Abandoned
-
2023
- 2023-07-14 US US18/352,769 patent/US20240174731A1/en not_active Abandoned
-
2024
- 2024-09-23 US US18/892,964 patent/US20250145688A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2016000284A (es) | Proteínas agonistas de los receptores de trail de cadena simple. | |
| CY1119098T1 (el) | Αγωνιστες fgfr1 και μεθοδοι χρησης | |
| MX2015017331A (es) | Anticuerpos anti fc similar a receptor 5 (fcrh5). | |
| BR112017009517A2 (pt) | receptores de antígeno quimérico anti-cldn e métodos de uso | |
| BR112017011932A2 (pt) | ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso? | |
| PE20181349A1 (es) | Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador | |
| CR20180594A (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo | |
| CL2015002654A1 (es) | Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso | |
| CL2015002357A1 (es) | Nuevos conjugados de anticuerpos y usos de los mismos | |
| ECSP17080639A (es) | Moléculas de unión a lag-3 y métodos de uso de las mismas | |
| MX2017000116A (es) | Moleculas basadas en il-15 y metodos para su uso. | |
| CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
| MX379136B (es) | Proteinas agonistas receptoras cd40 de cadena sencilla. | |
| MX375032B (es) | Proteínas de unión y métodos para utilizarlas. | |
| MX2016007958A (es) | Anticuerpos anti-cd3 y metodos de uso. | |
| MX2018013072A (es) | Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos. | |
| EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
| MX2016002574A (es) | Nuevos moduladores del homologo 6 (sez6) y metodos de uso. | |
| BR112016010822A2 (pt) | anticorpos específicos para fcrn | |
| MX2016002537A (es) | Anticuerpos y ensayos para la detección del receptor 1 de folato. | |
| CR20180348A (es) | Nuevos anticuerpos anti-claudina y sus métodos de uso | |
| BR112017023131A2 (pt) | anticorpos anti- fcrn | |
| CL2015002724A1 (es) | Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23 | |
| CR20150585A (es) | Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares | |
| UY36455A (es) | Antagonistas del receptor ep3 de prostaglandinas |